IGC Stock Forecast: IGC Pharma, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for IGC Pharma, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 14 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores IGC Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (84): The share price has been relatively steady.
Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IGC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IGC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Aug 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 23 Feb 2026 | Ascendiant Capital | Maintains | Buy | — |
| 9 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 26 Aug 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 Mar 2025 | Alliance Global Partners | Reiterates | Buy | — |
| 24 Feb 2025 | Ascendiant Capital | Maintains | Buy | — |
| 5 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 3 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 29 July 2024 | Ascendiant Capital | Maintains | Buy | — |
| 17 July 2024 | Alliance Global Partners | Initiates | Buy | — |
| 21 June 2024 | Ascendiant Capital | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IGC.
This page is one stock. Monday covers all of them.
IGC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IGC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, IGC Pharma, Inc. returned −45.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IGC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 18.1×
- Price / book
- 3.0×
- EV / EBITDA
- —
Cheaper than 8% of US stocks
Cheaper than 30% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 17.4%
- Operating margin
- —
- Net margin
- —
Higher than 17% of US stocks
- Return on equity
- −83.3%
- Return on assets
- −50.3%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IGC Pharma, Inc. has a market value of $21.0M and an enterprise value of $21.9M.
Revenue in the twelve months to 31 Mar 2026: $1.2M. The latest quarter shrank 3.9% year on year.
Net income over the same four quarters: −$6.5M, a −552.1% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$6.8M, after $631K of capital spending.
IGC Pharma, Inc. employs 70 people — $17K of revenue per employee.
Data provided by Twelve Data
IGC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IGC’s peer groups, ranked by the model: consumer staples stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own IGC Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IGC
What is the IGC stock price forecast for 2026-2027?
The median 12-month analyst price target for IGC Pharma, Inc. is $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IGC stock a buy right now?
Of the 1 analyst covering IGC Pharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IGC Pharma, Inc. 14 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IGC?
As at 21 Nov 2026, IGC Pharma, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (84 of 100).
Will IGC stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $6, and Ticker Nerd's factor model ranks IGC Pharma, Inc. 14 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IGC stock forecast for 2030?
No analyst covering IGC Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IGC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.
How has IGC stock performed over the past year?
IGC Pharma, Inc. returned -45.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does IGC Pharma, Inc. do?
IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies for Alzheimer’s disease and related neurodegenerative conditions. Its current pipeline centers on IGC-AD1, a cannabinoid-based investigational treatment for agitation in dementia associated with Alzheimer’s disease, alongside preclinical programs such as TGR-63 and other compounds targeting Alzheimer’s-related pathology and metabolic dysfunction.
About IGC Pharma, Inc.
IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies for Alzheimer’s disease and related neurodegenerative conditions. Its current pipeline centers on IGC-AD1, a cannabinoid-based investigational treatment for agitation in dementia associated with Alzheimer’s disease, alongside preclinical programs such as TGR-63 and other compounds targeting Alzheimer’s-related pathology and metabolic dysfunction. The company also develops AI-enabled tools, including MINT-AD and related healthcare applications, to support risk assessment, research, and clinical decision-making in cognitive disorders. IGC Pharma operates in the pharmaceutical and biotechnology sectors, with activities spanning drug discovery, clinical research, and the development of cannabinoid-based formulations for neurological and metabolic indications. Headquartered in Potomac, Maryland, the company serves the broader life sciences market through its focus on innovative treatments and technology-driven support tools for patients, caregivers, and healthcare providers.
CEO Mr. Ram Mukunda · 70 employees · United States · https://igcpharma.com